Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Mantle Cell Lymphoma: early-phase trial registry
46 of 103 indexed Mantle Cell Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #130 of 28,707 conditions by registered trial count.
103 US clinical trials · 46 currently recruiting · #130 of 28,707 conditions by registered trial count
Mantle Cell Lymphoma: 103 US clinical trials tracked, 46 recruiting.
Mantle Cell Lymphoma is the subject of 103 registered US clinical trials on ClinicalTrials.gov, 46 of them currently open to new participants. 7 are in Phase 3-4 (later-stage) and 86 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 12 of these trials.
Enrollment posture brief
Registry condition mantle-cell-lymphoma
OPEN 46 | RECR 45% | LATE 7 | EARLY 86 | RANK #130 | SPON 12
Volume-matched condition peers
Nearest open-share peer: Food Insecurity (45% recruiting · 38 trials)
Mantle Cell Lymphoma lists 46 open slots (45% of 103 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Mantle Cell Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Mantle Cell Lymphoma is recruiting above its size-band peers.
46 of 103 indexed trials (44.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Mantle Cell Lymphoma trials is spread across many organizations.
M.D. Anderson Cancer Center accounts for 12 of 103 trials (11.7%). 71 distinct sponsors appear on at least one study for this condition label.
-
Most Mantle Cell Lymphoma trials plan to enrol fewer than 100 people.
Median target enrolment is 43 among the 103 trials that report a genuine target (sentinel values excluded). 73 of those (70.9%) plan for fewer than 100 participants.
-
Mantle Cell Lymphoma research is mostly interventional.
96 interventional and 7 observational studies make up this index (93.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
103 total, page 1 of 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Janssen Research & Development
NCT01804686
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
BeOne Medicines
NCT05006716
Long-term Follow-up Study of Patients Receiving CAR-T Cells
Medical College of Wisconsin
NCT03375619
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Alliance for Clinical Trials in Oncology
NCT05976763
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
BeOne Medicines
NCT06742996
Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy
Adaptive Biotechnologies
NCT05255354
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
AstraZeneca
NCT06564038
Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
Emory University
NCT03501576
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
OncoNano Medicine
NCT06022029
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Stanford University
NCT06340737
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Iksuda Therapeutics
NCT05365659
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
National Heart, Lung, and Blood Institute (NHLBI)
NCT05724121
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
CRISPR Therapeutics
NCT05643742
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Carna Biosciences
NCT05602363
Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
Mayo Clinic
NCT06151730
Avo In R/R And Previously Untreated MCL
Austin I Kim
NCT04855695
CONFIRM: Magnetic Resonance Guided Radiation Therapy
Brigham and Women's Hospital
NCT04368702
Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
H. Lee Moffitt Cancer Center and Research Institute
NCT06553872
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Newave Pharmaceutical
NCT04775745
BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
Christine Ryan
NCT06854003
Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients
M.D. Anderson Cancer Center
NCT06263491
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
City of Hope Medical Center
NCT05861050
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
Emory University
NCT04883437
Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
OHSU Knight Cancer Institute
NCT06784167
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
Academic and Community Cancer Research United
NCT04626791
GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma
M.D. Anderson Cancer Center
NCT06522386
Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
City of Hope Medical Center
NCT06054776
A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma
Memorial Sloan Kettering Cancer Center
NCT06192888
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
C. Babis Andreadis
NCT04545762
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Vironexis Biotherapeutics
NCT06533579
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
University of California, San Francisco
NCT06252675
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
M.D. Anderson Cancer Center
NCT05529069
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
John Lister
NCT05281809
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
City of Hope Medical Center
NCT03523975
Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma
City of Hope Medical Center
NCT06572618
Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma
Alvaro Alencar, MD
NCT06029309
Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial
OHSU Knight Cancer Institute
NCT06357676
Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
University of Utah
NCT06300528
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Marcela V. Maus, M.D.,Ph.D.
NCT06026319
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
Fred Hutchinson Cancer Center
NCT06839053
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
UNC Lineberger Comprehensive Cancer Center
NCT04223765
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
Joshua Sasine, MD, PhD
NCT05887167
SynKIR-310 for Relapsed/Refractory B-NHL
Verismo Therapeutics
NCT06544265
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
Weill Medical College of Cornell University
NCT05934838
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
City of Hope Medical Center
NCT05432635
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Medical College of Wisconsin
NCT05990465
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
ECOG-ACRIN Cancer Research Group
NCT03267433
Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
Eastern Cooperative Oncology Group
NCT01415752
A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma
ECOG-ACRIN Cancer Research Group
NCT04115631
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
Merck Sharp & Dohme
NCT05458297
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 46 |
| Phase 2 | 40 |
| Phase 3 | 7 |
Top Sponsors
Named interventions
Most-linked intervention names on Mantle Cell Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Mantle Cell Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Mantle Cell Lymphoma page
103 registered trials, 46 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 46 Mantle Cell Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Mantle Cell Lymphoma trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Mantle Cell Lymphoma condition card totals 103 registered trials; most-linked intervention Rituximab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.